[{"address1": "1900 Lake Park Drive", "address2": "Suite 380", "city": "Smyrna", "state": "GA", "zip": "30080", "country": "United States", "phone": "678 384 7220", "fax": "678 384 7281", "website": "https://www.geovax.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. David Alan Dodd", "age": 73, "title": "Chairman, President & CEO", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 384200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark J. Newman Ph.D.", "age": 68, "title": "Chief Scientific Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 291500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kelly T. McKee Jr., M.D., M.P.H.", "age": 73, "title": "Chief Medical Officer", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 361034, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harriet Latham Robinson Ph.D.", "age": 85, "title": "Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board", "yearBorn": 1938, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark W. Reynolds CPA", "age": 61, "title": "CFO & Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 348200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  O'Brien", "title": "Vice President of Quality Systems & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey  Welch", "title": "Head of Process Development & Manufacturing Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Niles", "title": "Head of Commercial Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John W. Sharkey Ph.D.", "age": 67, "title": "Vice President of Business Development", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.84, "open": 3.83, "dayLow": 3.71, "dayHigh": 4.285, "regularMarketPreviousClose": 3.84, "regularMarketOpen": 3.83, "regularMarketDayLow": 3.71, "regularMarketDayHigh": 4.285, "beta": 3.078, "forwardPE": -4.5, "volume": 1279182, "regularMarketVolume": 1279182, "averageVolume": 7299569, "averageVolume10days": 6759620, "averageDailyVolume10Day": 6759620, "bid": 3.86, "ask": 3.9, "bidSize": 400, "askSize": 700, "marketCap": 32915664, "fiftyTwoWeekLow": 1.09, "fiftyTwoWeekHigh": 11.18, "priceToSalesTrailing12Months": 109.47184, "fiftyDayAverage": 3.4687, "twoHundredDayAverage": 3.225265, "currency": "USD", "enterpriseValue": 18793188, "floatShares": 3532680, "sharesOutstanding": 7209830, "sharesShort": 623333, "sharesShortPriorMonth": 261531, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1184, "heldPercentInsiders": 0.0053100004, "heldPercentInstitutions": 0.07634, "shortRatio": 0.33, "shortPercentOfFloat": 0.1193, "bookValue": -0.553, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -26915400, "trailingEps": -13.31, "forwardEps": -0.86, "lastSplitFactor": "1:20", "lastSplitDate": 1600992000, "enterpriseToRevenue": 62.503, "enterpriseToEbitda": -0.692, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GOVX", "underlyingSymbol": "GOVX", "shortName": "GeoVax Labs, Inc.", "longName": "GeoVax Labs, Inc.", "firstTradeDateEpochUtc": 1601040600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c7c31a63-264a-3189-a2f8-87643849f80c", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.87, "targetHighPrice": 120.0, "targetLowPrice": 10.0, "targetMeanPrice": 42.0, "targetMedianPrice": 19.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 1561712, "totalCashPerShare": 0.297, "ebitda": -27155956, "totalDebt": 142292, "quickRatio": 0.291, "currentRatio": 0.6, "totalRevenue": 300677, "revenuePerShare": 0.143, "returnOnAssets": -1.3434501, "returnOnEquity": -3.62391, "freeCashflow": -14219356, "operatingCashflow": -22998400, "operatingMargins": -16.83608, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]